Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radium-223 in men with advanced prostate cancer and bone metastases
ISRCTN12835467Phase 4Completed
- Sponsor
- Ospedale Spirito Santo
- Start
- Mar 2018
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of radium-223 dichloride in prostate cancer (PCa) and bone metastases, sponsored by Ospedale Spirito Santo. Primary endpoint: Overall survival. Started Mar 2018; status: completed.
02
Drugs
radium-223 dichloride
03
Conditions
prostate cancer (PCa)bone metastases
Beyond the preview
Go deeper on ISRCTN12835467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN12835467.